Risk stratification in hospitalized heart failure patients: do the RIGHT thing!

Excerpt

Heart failure with preserved ejection fraction (HFpEF) is intended to become a major challenge in the upcoming years for all clinicians. According to American forecasts, HFpEF prevalence will probably rise up by 2050 to 60% of all heart failure (HF) phenotypes, almost doubling the prevalence of heart failure with reduced ejection fraction (HFrEF) [1]. A peculiarity of HFpEF patients commonly display a higher load of complexity and unfortunately, an evidence-based treatment aimed at improving HFpEF outcomes is not to date available [2]. Indeed, most recent guidelines suggest as only recommended treatment the treatment of the underlying clinical conditions [2]. Thereby, the identification of a cluster of patients burdened by a more severe syndrome is extremely helpful to implement more aggressive strategies and closer follow-ups. …